Health Canada approves Profound Medical’s TULSA-PRO system

Profound Medical

Health Canada approved the sale of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO system for the ablation of low-to intermediate-risk organ-confined prostate cancer.

TULSA-PRO is a transurethral prostate tissue ablation system that combines real-time MRI with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.

The system is designed to provide customizable and predictable, incision-free and radiation-free prostate ablation while actively protecting the urethra and rectum with water cooling to preserve men’s functional abilities.

In April 2015, Profound licensed distribution of TULSA-PRO in Canada to Knight Therapeutics (TSX:GUD) and noted that commercial opportunity for TULSA-PRO in that country will be modest until such time that government reimbursement is established.

“The positive Health Canada decision is key to our global expansion strategy for TULSA-PRO, as many major market jurisdictions, such as China, have a ‘country of origin’ approval requirement for medical devices,” Goldy Singh, Profound’s VP of regulatory affairs and product management, said in a statement.

In August, Profound received 510(k) clearance from the FDA to market TULSA-PRO for prostate tissue ablation procedures indiscriminate of tissue type, including malignant and benign, and the company commercially launched the technology in the U.S. earlier this quarter.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.